The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders
Autor: | Elena Toniato, Stefano Martinotti, Vincenzo Flati, Giulia Giambuzzi, Vincenzo De Iuliis, Jacopo Di Gregorio, Sonia Spalletta, Pio Conti, Iole Robuffo |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
TGF-β
autophagy Inflammation Review SMADs Extracellular matrix Cell and Developmental Biology Wnt Fibrosis Medicine Epithelial–mesenchymal transition lcsh:QH301-705.5 Loss function business.industry Autophagy fibrosis Wnt signaling pathway EMT Cell Biology medicine.disease Crosstalk (biology) lcsh:Biology (General) inflammation Cancer research medicine.symptom business Developmental Biology |
Zdroj: | Frontiers in Cell and Developmental Biology, Vol 8 (2020) Frontiers in Cell and Developmental Biology |
DOI: | 10.3389/fcell.2020.607483/full |
Popis: | Fibrosis is a chronic and progressive disorder characterized by excessive deposition of extracellular matrix, which leads to scarring and loss of function of the affected organ or tissue. Indeed, the fibrotic process affects a variety of organs and tissues, with specific molecular background. However, two common hallmarks are shared: the crucial role of the transforming growth factor-beta (TGF-β) and the involvement of the inflammation process, that is essential for initiating the fibrotic degeneration. TGF-β in particular but also other cytokines regulate the most common molecular mechanism at the basis of fibrosis, the Epithelial-to-Mesenchymal Transition (EMT). EMT has been extensively studied, but not yet fully explored as a possible therapeutic target for fibrosis. A deeper understanding of the crosstalk between fibrosis and EMT may represent an opportunity for the development of a broadly effective anti-fibrotic therapy. Here we report the evidences of the relationship between EMT and multi-organ fibrosis, and the possible therapeutic approaches that may be developed by exploiting this relationship. |
Databáze: | OpenAIRE |
Externí odkaz: |